These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1867648)

  • 1. Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type.
    Adams M; Lennard MS; Otton SV; Tucker GT; Woods HF
    Biochem Pharmacol; 1991 Jul; 42(4):947-9. PubMed ID: 1867648
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
    Lennard MS
    Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquine/sparteine-type polymorphic drug metabolism in wild Clethrionomys rufocanus.
    Hoshi H; Masuda M; Yamamoto Y; Suimamoto Y; Kazusaka A; Fujita S
    Drug Metab Dispos; 1995 Nov; 23(11):1301-3. PubMed ID: 8591735
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract]   [Full Text] [Related]  

  • 7. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
    Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF
    Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P; Kronbach T; Eichelbaum M; Meyer UA
    Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.
    Clark DW; Edwards IR
    Med Toxicol Adverse Drug Exp; 1988; 3(3):241-7. PubMed ID: 3398777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
    Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
    Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
    Ho JW; Moody DE
    Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically determined polymorphisms in drug oxidation.
    Jacqz E; Hall SD; Branch RA
    Hepatology; 1986; 6(5):1020-32. PubMed ID: 3758933
    [No Abstract]   [Full Text] [Related]  

  • 18. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
    Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.